Basal ganglia dysfunction in idiopathic REM sleep behaviour disorder parallels that in early Parkinson's disease.
SEE POSTUMA DOI101093/AWW131 FOR A SCIENTIFIC COMMENTARY ON THIS ARTICLE: Resting state functional magnetic resonance imaging dysfunction within the basal ganglia network is a feature of early Parkinson's disease and may be a diagnostic biomarker of basal ganglia dysfunction. Currently, it is unclear whether these changes are present in so-called idiopathic rapid eye movement sleep behaviour disorder, a condition associated with a high rate of future conversion to Parkinson's disease. In this study, we explore the utility of resting state functional magnetic resonance imaging to detect basal ganglia network dysfunction in rapid eye movement sleep behaviour disorder. We compare these data to a set of healthy control subjects, and to a set of patients with established early Parkinson's disease. Furthermore, we explore the relationship between resting state functional magnetic resonance imaging basal ganglia network dysfunction and loss of dopaminergic neurons assessed with dopamine transporter single photon emission computerized tomography, and perform morphometric analyses to assess grey matter loss. Twenty-six patients with polysomnographically-established rapid eye movement sleep behaviour disorder, 48 patients with Parkinson's disease and 23 healthy control subjects were included in this study. Resting state networks were isolated from task-free functional magnetic resonance imaging data using dual regression with a template derived from a separate cohort of 80 elderly healthy control participants. Resting state functional magnetic resonance imaging parameter estimates were extracted from the study subjects in the basal ganglia network. In addition, eight patients with rapid eye movement sleep behaviour disorder, 10 with Parkinson's disease and 10 control subjects received (123)I-ioflupane single photon emission computerized tomography. We tested for reduction of basal ganglia network connectivity, and for loss of tracer uptake in rapid eye movement sleep behaviour disorder and Parkinson's disease relative to each other and to controls. Connectivity measures of basal ganglia network dysfunction differentiated both rapid eye movement sleep behaviour disorder and Parkinson's disease from controls with high sensitivity (96%) and specificity (74% for rapid eye movement sleep behaviour disorder, 78% for Parkinson's disease), indicating its potential as an indicator of early basal ganglia dysfunction. Rapid eye movement sleep behaviour disorder was indistinguishable from Parkinson's disease on resting state functional magnetic resonance imaging despite obvious differences on dopamine transported single photon emission computerized tomography. Basal ganglia connectivity is a promising biomarker for the detection of early basal ganglia network dysfunction, and may help to identify patients at risk of developing Parkinson's disease in the future. Future risk stratification using a polymodal approach could combine basal ganglia network connectivity with clinical and other imaging measures, with important implications for future neuroprotective trials in rapid eye movement sleep behaviour disorder.
1 Oxford Parkinson's Disease Centre (OPDC), Oxford, UK 2 Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Michal
M
Rolinski
3 Centre for the functional MRI of the Brain (FMRIB), University of Oxford, Oxford, UK.
Ludovica
L
Griffanti
4 Division of Clinical Neurosciences and MRC Clinical Sciences Centre, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London, UK.
Paola
P
Piccini
4 Division of Clinical Neurosciences and MRC Clinical Sciences Centre, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London, UK.
Andreas A
AA
Roussakis
1 Oxford Parkinson's Disease Centre (OPDC), Oxford, UK 2 Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Konrad
K
Szewczyk-Krolikowski
3 Centre for the functional MRI of the Brain (FMRIB), University of Oxford, Oxford, UK.
Ricarda A
RA
Menke
5 Respiratory Support and Sleep Centre, Papworth Hospital, Cambridge, UK.
Timothy
T
Quinnell
6 Department of Clinical Neurophysiology, John Radcliffe Hospital, Oxford, UK.
Zenobia
Z
Zaiwalla
1 Oxford Parkinson's Disease Centre (OPDC), Oxford, UK 2 Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK 3 Centre for the functional MRI of the Brain (FMRIB), University of Oxford, Oxford, UK.
Johannes C
JC
Klein
1 Oxford Parkinson's Disease Centre (OPDC), Oxford, UK 3 Centre for the functional MRI of the Brain (FMRIB), University of Oxford, Oxford, UK 7 Department of Psychiatry, University of Oxford, Oxford, UK.
Clare E
CE
Mackay
1 Oxford Parkinson's Disease Centre (OPDC), Oxford, UK 2 Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK michele.hu@ndcn.ox.ac.uk.
Michele T M
MT
Hu
D000368:Aged; D001480:Basal Ganglia Diseases / Q000000981:diagnostic imaging / Q000378:metabolism / Q000503:physiopathology; D005260:Female; D059907:Functional Neuroimaging / Q000379:methods*; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000000981:diagnostic imaging / Q000378:metabolism / Q000503:physiopathology; D020187:REM Sleep Behavior Disorder / Q000000981:diagnostic imaging / Q000378:metabolism / Q000503:physiopathology; D015899:Tomography, Emission-Computed, Single-Photon
Parkinson’s disease; imaging; rapid eye movement sleep behaviour disorder